UW21125
OPEN TO ACCRUAL
Ph 1 Study of GS-1811 alone and with Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors
EAY191
OPEN TO ACCRUAL
Molecular Analysis for Combination Therapy Choice (ComboMATCH)
EAY191A3
OPEN TO ACCRUAL
A ComboMATCH Treatment Trial: Palbociclib and Binimetinib in RAS-Mutant Cancers
EAY191E5
OPEN TO ACCRUAL
A Randomized Phase II Study of AMG 510 (Sotorasib) with or without Panitumumab in Advanced Solid Tum
NCI10528
OPEN TO ACCRUAL
PH1 Study of (POL0) in BRCA-mutant and other DNA Damage Repair-Deficient Solid Tumors
UW22141
OPEN TO ACCRUAL
PH1/2 Study of IMC-F106C as Monotherapy/Combination w/Checkpoint Inhibitors in PRAME-Positive Cancer
UW23006
OPEN TO ACCRUAL
PH1/2 Study of DF9001 Alone and in Combination with Nivolumab in pts with Advanced Solid Tumors
UW23053
OPEN TO ACCRUAL
PH1 Study of KO-2806 Administered as Monotherapy & in Combination in Adults w/ Advanced Solid Tumors
UW23087
OPEN TO ACCRUAL
Ph1/2 Study to Investigate NDI-101150 as monotherapy & in combo with Pembro in Pts w/ Solid Tumors
UW23088
OPEN TO ACCRUAL
PH1/2 Study of CFT1946 alone & combo therapy in subjects w/ BRAFT-V600 Mutant Solid Tumors
UW23126
OPEN TO ACCRUAL
A Phase 1a/1b Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
UW23136
OPEN TO ACCRUAL
PH1 Study ASP1570 & Combination w/ Pembrolizumab in pts w/ Locally Advanced or Metastatic Tumors
UW24010
OPEN TO ACCRUAL
Ph 1/2a Study of IMM-1-104, Oral MEK 1/2 Inhibitor in Pts w/ Previously Treated RAS Solid Tumors
UW24012
OPEN TO ACCRUAL
Ph 1b/2 Study of Disitamab Vedotin alone and with Other Anticancer Therapies in Solid Tumors
UW24033
OPEN TO ACCRUAL
PH1/2 Study BBI-355 alone & w/Targeted Therapies in subjects w/ Solid Tumor Oncogene Amplifications